Table 1

Baseline characteristics


All patientsPatients with MIPatients without MI
No of patients8432848348
Age, years (SD)61.7 (12.7)66.5 (12.3)61.7 (12.7)
Women, n (%)4163 (49)29 (35)4134 (50)
Index visit data
0-hour hs-cTnT concentration (ng/L), median (IQR)6.0 (3.3)8.8 (3.6)6.0 (3.3)
Delta hs-cTnT (ng/L), mean (SD)*0.4 (4.9)13.8 (20.0)0.3 (4.3)
Early retest (45 min to <2 hours), n (%)3847 (46)26 (31)3821 (46)
Late retest (2 hours to ≤3.5 hours), n (%)4585 (54)58 (69)4527 (54)
Time from 0-hour hs-cTnT to second hs-cTnT measurement, min, median (IQR)133 (101)175 (94)132 (101)
 Early retest group (45 min to <2 hours), n (%)77 (27)75 (31)77 (27)
 Late retest group (2 to ≤3.5 hours), n (%)179 (28)181 (18)178 (28)
Historical hs-cTnT concentration (ng/L), median (IQR)6.3 (4.6)9.0 (11.8)6.3 (4.5)
Time from historical hs-cTnT to 0-hour hs-cTnT measurement, days, median (IQR)207 (464)169 (531)208 (463)
Comorbidities
Prior stroke, n (%)506 (6.0)3 (3.6)503 (6.0)
Prior MI, n (%)2017 (24)44 (52)1973 (24)
COPD, n (%)538 (6.4)6 (7.1)532 (6.4)
Prior heart failure, n (%)345 (4.1)3 (3.6)342 (4.1)
Diabetes, n (%)1012 (12)23 (27)989 (12)
Chronic kidney disease (eGFR <60 mL/min/1.73 m2), n (%)65 (0.8)2 (2.4)63 (0.8)
Peripheral arterial disease, n (%)90 (1.1)6 (7.1)84 (1.0)
Prior coronary angiography, n (%)3100 (37)53 (63)3047 (37)
Prior revascularisation, n (%)2375 (28)44 (52)2331 (28)
Medication
Aspirin, n (%)3046 (36)51 (61)2995 (36)
P2Y12 inhibitor†, n (%)1243 (15)27 (32)1216 (15)
Beta-blockers, n (%)3930 (47)57 (68)3873 (46)
ACE/ARB, n (%)3635 (43)50 (60)3585 (43)
Statins, n (%)3450 (41)53 (63)3397 (41)
OAC, n (%)1030 (12)9 (11)1021 (12)
Warfarin, n (%)687 (8.1)8 (9.5)679 (8.1)
NOAC, n (%)383 (4.5)2 (2.4)381 (4.6)
  • *Delta hs-cTnT between the 0-hour hs-cTnT and second hs-cTnT measurements.

  • †P2Y12 inhibitor, including clopidogrel, ticagrelor or prasugrel.

  • ACEi/ARB, ACE inhibitor/angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NOAC, new oral anticoagulant; OAC, oral anticoagulants.